APA (7th ed.) Citation

Peterlin, P., Gaschet, J., Turlure, P., Gourin, M., Dumas, P., Thepot, S., . . . Chevallier, P. FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: A study from the Groupe Francophone des Myélodysplasies. Ferrata Storti Foundation.

Chicago Style (17th ed.) Citation

Peterlin, Pierre, et al. FLT3 Ligand Kinetic Profile Predicts Response to Treatment in Patients with High-risk Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia Receiving CPX-351: A Study from the Groupe Francophone Des Myélodysplasies. Ferrata Storti Foundation.

MLA (9th ed.) Citation

Peterlin, Pierre, et al. FLT3 Ligand Kinetic Profile Predicts Response to Treatment in Patients with High-risk Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia Receiving CPX-351: A Study from the Groupe Francophone Des Myélodysplasies. Ferrata Storti Foundation.